---
title: "Enanta Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 17.16 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285988788.md"
datetime: "2026-05-11T20:08:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285988788.md)
  - [en](https://longbridge.com/en/news/285988788.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285988788.md)
---

# Enanta Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 17.16 M

Revenue: As of FY2026 Q2, the actual value is USD 17.16 M, beating the estimate of USD 17.09 M.

EPS: As of FY2026 Q2, the actual value is USD -0.45, beating the estimate of USD -0.4873.

EBIT: As of FY2026 Q2, the actual value is USD -10.62 M.

The provided reference, an 8-K filing by Enanta Pharmaceuticals, Inc. dated May 11, 2026, announces the release of its financial results for the fiscal quarter ended March 31, 2026, via a press release (Exhibit 99.1). However, the actual financial and operational metrics, including segment revenue, net income, gross margin, operating profit, operating costs, cash flow, unique metrics, or outlook/guidance, are not contained within this 8-K filing itself. Therefore, no specific financial or operational data can be extracted from the given text .

### Related Stocks

- [ENTA.US](https://longbridge.com/en/quote/ENTA.US.md)

## Related News & Research

- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story](https://longbridge.com/en/news/286658162.md)
- [Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital](https://longbridge.com/en/news/286648720.md)
- [Ultragenyx Shareholders Approve Incentive Plan, Elect Directors](https://longbridge.com/en/news/286809118.md)